DiaMedica Therapeutics Inc (DMAC)
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on therapies for severe ischemic diseases. Its lead program, DM199, is a recombinant form of human tissue kallikrein-1 being studied in Phase 2/3 trials for acute ischemic stroke and in Phase 2 trials for preeclampsia, cardiorenal disease, and fetal growth restriction. The company is also advancing DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory conditions, including acute pancreatitis. Formerly known as DiaMedica Inc., the company adopted its current name in December 2016. Founded in 2000, DiaMedica Therapeutics is headquartered in Minneapolis, Minnesota.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DMAC
|
$5.90
|
-16.8% Downside
|
Fair
|
$15.50
|
118.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-10.8x
|
8.0x
|
—
|
377.7 M
|
329 M
|
0.1%
|
53.4%
|
32.7
|
—
|
88.4%
|
